Rare diseases, real opportunity: Why the UK’s next challenge...
The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Newsletters and Deep Dive digital magazine
The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."
GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
Editor's Picks
Newsletters and Deep Dive
digital magazine